This chapter offers an overview of dengue vaccines that have advanced to clinical trials, addressing the intricate challenges in their development. It details the complexities of the dengue virus, including its four serotypes and the phenomenon of antibody-dependent enhancement (ADE), which significantly impacts vaccine design. The chapter reviews the historical trajectory and current landscape of vaccine candidates, such as Dengvaxia®, Qdenga®, and Butantan-DV, analyzing their efficacy, safety profiles, and the lessons learned from their clinical trials. It also discusses other hurdles like suitable animal models and viral interference. Ultimately, the chapter highlights the advancements made and outlines future research directions crucial for a universally effective dengue vaccine.